Andrea Wang Gillam, MD
Medical Oncology · Saint Louis, MONPI 1740488766
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,325 of the $18,876 with a category attached, or 91.8%. 6 manufacturers reported payments, led by AstraZeneca at 34.4% of the total. Reporting peaked in 2020 at $13,481 and has fallen 99.9% since, to $19 in 2021.
Across 23 payments — averaging $820.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Eisai Inc.$5K
- Merck$4K
- Bayer$2K
- Aurobindo Pharma USA, Inc.$700
- Amgen$114
Across 75 payments — averaging $20,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$412K
- Takeda Pharmaceuticals U.S.A., Inc.$289K
- E.r. Squibb & Sons, L.L.C.$273K
- Merck$204K
- Ipsen Biopharmaceuticals, Inc$197K
- Pfizer$74K
- plus $112K from 6 others
What the payments were for
- Consulting fees$17,32592%
- Travel & lodging$1,1566%
- Food & beverage$3842%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $6,500 |
| Eisai Inc. | 12 | $5,261 |
| Merck | 6 | $4,300 |
| Bayer | 1 | $2,000 |
| Aurobindo Pharma USA, Inc. | 1 | $700 |
| Amgen | 2 | $114 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,876 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
- Maurice WillisSaint Louis$101K
- Moh'd KhushmanSaint Louis$84K
- Camille AbboudSaint Louis$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.